Rank #1270KNSA

Kiniksa Pharmaceuticals Interna

$47.17

3.92% (Daily)

Market Cap

$3.58B

Revenue

$597.97M

Rank by MCap

#1270

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Sanj K. Patel

Headquarters

London

Employees

315

About Kiniksa Pharmaceuticals Interna

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a ch...